Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoLBAt trial of LB-100 plus atezolizumab in metastatic MSS colorectal cancer
NL-OMON60805Phase 1Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LB-100 and atezolizumab in colorectal cancer (CRC) and microsatellite stable colorectal cancer, sponsored by Netherlands Cancer Institute. Primary endpoints: Recommended phase 2 dose, Maximum tolerated dose and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
LB-100atezolizumab
03
Conditions
colorectal cancer (CRC)microsatellite stable colorectal cancer
Beyond the preview
Go deeper on NL-OMON60805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60805.